FDA initiates clinical hold on Cellectis ’ UCART123 trials

The US Food and Drug Administration (FDA) has initiated a clinical hold on Phase I trials of biopharmaceutical firm Cellectis ’ universal chimeric antingen receptor T-cells (UCARTs) product candidate UCART123.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news